Three-arm phase II trial comparing camrelizumab plus chemotherapy versus camrelizumab plus chemoradiation versus chemoradiation as preoperative treatment for locally advanced esophageal squamous cell carcinoma (NICE-2 Study)

Three-arm phase II trial comparing camrelizumab plus chemotherapy versus camrelizumab plus chemoradiation versus chemoradiation as preoperative treatment for locally advanced esophageal squamous cell carcinoma (NICE-2 Study)

Abstract Background Preoperative chemoradiotherapy (CRT) with CROSS regimen has been the recommended treatment for locally advanced esophageal squamous cell carcinoma (ESCC). The addition of programmed cell death protein 1 (PD-1) inhibitor to preoperative CRT may further improve oncologic results. P...

Full description

Bibliographic Details
Main Authors: Yang Yang, Li Zhu, Yan Cheng, Zhichao Liu, Xiaoyue Cai, Jinchen Shao, Ming Zhang, Jun Liu, Yifeng Sun, Yin Li, Jun Yi, Bentong Yu, Hongjing Jiang, Hezhong Chen, Hong Yang, Lijie Tan, Zhigang Li
Format: Article
Language:English
Published: BMC 2022-05-01
Series:BMC Cancer
Subjects:
Esophageal cancer
Camrelizumab
Chemoradiotherapy
Chemotherapy
Clinical trial
Online Access:https://doi.org/10.1186/s12885-022-09573-6

Internet

https://doi.org/10.1186/s12885-022-09573-6

Similar Items